Nimodipina Eg (Nimodipine)

Nimodipine blocks L‑type voltage‑gated calcium channels on the smooth muscle of cerebral arteries. This inhibition reduces calcium entry, causing the vessels to relax and dilate, thereby decreasing vasospasm and improving cerebral perfusion without causing major systemic blood‑pressure changes.

The exact dose of Nimodipina Eg is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other concurrent therapies. Healthcare professionals follow local guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Nimodipina Eg product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimodipine is a dihydropyridine with high affinity for cerebral vessels, making it especially effective for preventing vasospasm after subarachnoid hemorrhage. Other calcium‑channel blockers, such as nicardipine or verapamil, are less selective for cerebral arteries and are typically used for systemic hypertension rather than targeted neurovascular protection.

Nimodipina Eg should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and humidity, and ensure the container is tightly closed when not in use.

The medication is taken orally, usually with a glass of water. It may be administered with or without food, depending on the prescriber’s instructions, and the patient should follow the dosing schedule provided by the healthcare professional.

Serious adverse events include severe hypotension, myocardial infarction, hepatic dysfunction, and rare allergic reactions such as anaphylaxis. Patients should be monitored for sudden drops in blood pressure, chest pain, jaundice, or signs of an allergic response, and report any concerning symptoms promptly.

Nimodipina Eg is contraindicated in individuals with known hypersensitivity to nimodipine or other dihydropyridine calcium‑channel blockers, patients with severe hypotension, cardiogenic shock, or recent myocardial infarction. Clinicians should also exercise caution in patients with significant liver disease or uncontrolled cardiac conditions.